Study: Pharma getting more drugs approved, but less money for them

Share this article:
As companies begin their fourth-quarter tabulations, Deloitte and Thomson Reuters took their third annual look at industry's R&D-ROI balance and found that things are...OK—could be better, could be worse. The firms did not name names, but assessed the industry's financial success based on 12 companies, of which 10 showed net gains in their pipelines, and five “reported net commercial success.”

Among the study's findings:
  • The cost of developing pharmaceutical assets has been relatively flat, rising bout 4% between over the past two years, from just over $1 billion in 2010 to over $1.1 billion in 2012.

  • The industry's seen a jump in approvals, with 41 between 2011 and 2012, up from 32 between 2010 and 2011.

  • Although the approvals have been on the upswing, the projected value has not kept pace. Researchers said the 41 approvals in the 2011-2012 season amounted to $211 billion in projected sales, down from the $309 billion in forecasted sales of the 32 items approved the year before.

  • The 12 benchmark companies haven't been able to reduce the number of failed projects, and researchers wrote companies can reduce financial “leakage” by leaving projects earlier in the development process than waiting until later. Researchers also recommended repurposing failed compounds as a way to recoup  losses.

The proposed solutions cover familiar ground for the industry and its observers and include seeking out innovation from external sources, cultivating prescriber/payer relationships, create early-stage analysis and risk-sharing partnerships.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...